Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Updated Meta-analysis of the TP53 Arg72Pro Polymorphism and Gastric Cancer Risk

  • Xiang, Bin (Department of Gastroenterology, the Affiliated Jiangyin Hospital of Southeast University Medical School) ;
  • Mi, Yuan-Yuan (The Third Affiliated Hospital of Nantong University) ;
  • Li, Teng-Fei (Department of Gastroenterology, the Affiliated Jiangyin Hospital of Southeast University Medical School) ;
  • Liu, Peng-Fei (Department of Gastroenterology, the Affiliated Jiangyin Hospital of Southeast University Medical School)
  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The p53 tumor suppressor pathway plays an important role in gastric cancer (GC) development. Auto-regulatory feedback control of p53 expression is critical to maintaining proper tumor suppressor function. So far, several studies between p53 Arg72Pro polymorphism and GC have generated controversial and inconclusive results. Methods: To better assess the purported relationship, we performed a meta-analysis of 19 publications. Eligible studies were identified by searching the Pubmed database. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess any link. Results: Overall, a significant association was detected between the p53 Arg72Pro polymorphism and GC risk (Pro-allele vs. Arg-allele: OR = 1.05, 95%CI = 1.01-1.08; Pro/Pro vs. Arg/Arg: OR = 1.13, 95%CI = 1.04-1.22). Moreover, on stratified analysis by race, significantly increased risk was found for Asian populations (Pro-allele vs. Arg-allele: OR = 1.06, 95%CI = 1.02-1.10; Pro/Pro vs. Arg/Arg: OR = 1.16, 95%CI = 1.07-1.26; Pro/Pro+Pro/Arg vs. Arg/Arg: OR = 1.58, 95%CI = 1.09-2.27). Conclusions: Our study provided evidence that the p53 72Pro allele may increase GC risk in Asians. Future studies with larger sample size are warranted to further confirm this association in more detail.

Keywords

References

  1. Bergamaschi D, Gasco M, Hiller L, et al (2003). p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3, 387-402. https://doi.org/10.1016/S1535-6108(03)00079-5
  2. Birgander R, Sjalander A, Zhou Z, et al (1996). p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum Hered, 46, 49-54. https://doi.org/10.1159/000154325
  3. Capella G, Pera G, Sala N, et al (2008). DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study. Int J Epidemiol, 37, 1316-25. https://doi.org/10.1093/ije/dyn145
  4. De Feo E, Persiani R, La Greca A, et al (2009). A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. Mutat Res, 675, 60-5. https://doi.org/10.1016/j.mrgentox.2009.02.009
  5. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  6. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in metaanalysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  7. Etienne MC, Chazal M, Laurent-Puig P, et al (2002). Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol, 20, 2832-43. https://doi.org/10.1200/JCO.2002.09.091
  8. Gao L, Nieters A, Brenner H (2009). Cell proliferation-related genetic polymorphisms and gastric cancer risk: systematic review and meta-analysis. Eur J Hum Genet, 17, 1658-67. https://doi.org/10.1038/ejhg.2009.102
  9. Gomes de Souza L, Miranda de Lima J, Dale Cotrim Guerreiro da Silva I, Manoukian Forones N (2009). P53 Arg72Pro polymorphism in gastric cancer patients. J Gastrointest Cancer, 40, 41-5. https://doi.org/10.1007/s12029-009-9078-7
  10. Hamajima N, Matsuo K, Suzuki T, et al (2002). No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett, 181, 81-5. https://doi.org/10.1016/S0304-3835(02)00041-1
  11. Hiyama T, Tanaka S, Kitadai Y, et al (2002). p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer, 100, 304-8. https://doi.org/10.1002/ijc.10483
  12. Ihsan R, Devi TR, Yadav DS, et al (2011). Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, betel quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol, 30, 163-71. https://doi.org/10.1089/dna.2010.1119
  13. Katkoori VR, Jia X, Shanmugam C, et al (2009). Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res, 15, 2406-16. https://doi.org/10.1158/1078-0432.CCR-08-1719
  14. Ke-Xiang Z, Yu-Min L, Xun L, et al (2012). Study on the association of p53 codon 72 polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu Province in China. Mol Biol Rep, 39, 723-8. https://doi.org/10.1007/s11033-011-0791-5
  15. Kim N, Cho SI, Lee HS, et al (2010). The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea. Dig Dis Sci, 55, 101-10. https://doi.org/10.1007/s10620-008-0688-x
  16. Lai KC, Chen WC, Tsai FJ, Li SY, Jeng LB (2005). Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer. Hepatogastroenterology, 52, 944-8.
  17. Lane DP (1992). Cancer. p53, guardian of the genome. Nature, 358, 15-6. https://doi.org/10.1038/358015a0
  18. Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell, 88, 323-31. https://doi.org/10.1016/S0092-8674(00)81871-1
  19. Li Y, Prives C (2007). Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene, 26, 2220-5. https://doi.org/10.1038/sj.onc.1210311
  20. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  21. Mojtahedi Z, Haghshenas MR, Hosseini SV, Fattahi MJ, Ghaderi A (2010). p 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer, 47, 31-4. https://doi.org/10.4103/0019-509X.58856
  22. Mu LN, Lu QY, Yu SZ, et al (2005). Green tea drinking and multigenetic index on the risk of stomach cancer in a Chinese population. Int J Cancer, 116, 972-83. https://doi.org/10.1002/ijc.21137
  23. Papadakis EN, Dokianakis DN, Spandidos DA (2000). p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun, 3, 389-92. https://doi.org/10.1006/mcbr.2000.0241
  24. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  25. Perez-Perez GI, Bosques-Padilla FJ, Crosatti ML, Tijerina-Menchaca R, Garza-Gonzalez E (2005). Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. Scand J Gastroenterol, 40, 56-60. https://doi.org/10.1080/00365520410009456
  26. Shen H, Solari A, Wang X, et al (2004). P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep, 11, 1115-20.
  27. Shepherd T, Tolbert D, Benedetti J, et al (2002). Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology, 118, 1039-44.
  28. Shirai O, Ohmiya N, Taguchi A, et al (2010). P53, p21, and p73 gene polymorphisms in gastric carcinoma. Hepatogastroenterology, 57, 1595-601.
  29. Sjalander A, Birgander R, Hallmans G, et al (1997). p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis, 17, 1313-6.
  30. Song HR, Kweon SS, Kim HN, et al (2011). p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer, 14, 242-8. https://doi.org/10.1007/s10120-011-0034-4
  31. Sul J, Yu GP, Lu QY, et al (2006). P53 Codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions. Cancer Lett, 238, 210-23. https://doi.org/10.1016/j.canlet.2005.07.004
  32. Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19, 1092-100. https://doi.org/10.1128/MCB.19.2.1092
  33. Vogelstein B, Lane D, Levine AJ (2002). Surfing the p53 network. Nature, 408, 307-10.
  34. Vousden KH, Lane DP (2007). p53 in health and disease. Nat Rev Mol Cell Biol, 8, 275-83. https://doi.org/10.1038/nrm2147
  35. Walker KK, Levine AJ (1996). Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA, 93, 15335-40. https://doi.org/10.1073/pnas.93.26.15335
  36. Wang YC, Lee HS, Chen SK, Chang YY, Chen CY (1999). Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer, 35, 226-30. https://doi.org/10.1016/S0959-8049(98)00369-4
  37. Wu MT, Chen MC, Wu DC (2004). Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. Cancer Lett, 205, 61-8. https://doi.org/10.1016/j.canlet.2003.11.026
  38. Xi YG, Ding KY, Su XL, et al (2004). p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis, 25, 2201-6. https://doi.org/10.1093/carcin/bgh229
  39. Yi SY, Lee WJ (2006). A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer. World J Gastroenterol, 12, 6536-9. https://doi.org/10.3748/wjg.v12.i40.6536
  40. Zhang ZW, Newcomb P, Hollowood A, et al (2003). Ageassociated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res, 9, 2151-6.
  41. Zhang ZW, Newcomb P, Hollowood A, et al (2004). A comparison study of gastric cancer risk in patients with duodenal and gastric ulcer: roles of gastric mucosal histology and p53 codon 72 polymorphism. Dig Dis Sci, 49, 254-9. https://doi.org/10.1023/B:DDAS.0000017447.02220.f5
  42. Zhou Y, Li N, Zhuang W, et al (2007). P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer, 121, 1481-6. https://doi.org/10.1002/ijc.22833

Cited by

  1. p53 Codon 72 Polymorphism Interactions with Dietary and Tobacco Related Habits and Risk of Stomach Cancer in Mizoram, India vol.15, pp.2, 2014, https://doi.org/10.7314/APJCP.2014.15.2.717
  2. No Evidence of Association of the Arg72Pro p53 Gene Polymorphism with Cancer Risk in the Saudi Population: a Meta-Analysis vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5663
  3. Association between Polymorphisms in Inflammatory Response-Related Genes and the Susceptibility, Progression and Prognosis of the Diffuse Histological Subtype of Gastric Cancer vol.9, pp.12, 2018, https://doi.org/10.3390/genes9120631